Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which negatively impact their quality of life (QoL). Novel agents, including JAK inhibitors, have demonstrated an ability to reduce symptom burden in patients with MPNs, and there is ongoing research aimed at improving symptom management and QoL in these patients.

In this podcast, you will hear from Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, who discuss the importance of understanding and addressing QoL in patients with MPNs, and further highlight strategies to improve symptom management.